Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sinovac RSV mRNA vaccine safety in adults
NCT07418229Phase 1Not yet recruiting
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Mar 2026
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Sinovac RSV mRNA vaccine in respiratory syncytial virus infection (RSV) (3 arms), sponsored by Sinovac Biotech Ltd. Primary endpoint: Incidence of adverse events at 30 days. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
Sinovac RSV mRNA vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07418229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07418229.